Sarcome de Kaposi: traitement par facteur de transfert et interféron-alpha-2

Abstract

Immunotherapy with interferon and transfer factor has been tried in 2 cases of Kaposi’s sarcoma of the Mediterranean type, without visceral involvement. Clinical benefits appeared almost worthless and biological data hardly improved. On the contrary, side effects such as leucopenia, malaise, mental confusion proved quite impressive. From these 2 observations it might be concluded that interferon is not the treatment of choice of Kaposi’s sarcoma. Transfer factor, much more easy to use, displayed transient efficacity in 1 patient. Fundamentals about Kaposi’s sarcoma and interferon are reviewed.

Classic Kaposi's Sarcoma: A Review of 90 Cases

“…Literature reports on the use of BRM has still scarce and mainly concern second line therapies. Bourland (14) treated 2 chemotherapy resistant CKS cases with alpha-z-interferon (IFN) at high doses and reported no response. Contu (15) used high dose alpha-2a-IFN at 5 x 10 6 IU/m 2 intramuscularly 3 times weekly, and obtained one complete remission lasting 18 months and 2 partial remissions lasting 4 and 24 months respectively.…”